

# Minesh P Mehta

## List of Articles by Year in descending order

Source: [//exaly.com/author-pdf/4699731/publications.pdf](https://exaly.com/author-pdf/4699731/publications.pdf)

Version: 2025-02-01

407

PR articles

27,432

PR citations

5905

78

PR h-index

6105

160

g-index

482

documents

38599

doc citations

3842

93

h-index

36302

citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of 3D-TSE sequence-based radiosurgery in prolonging time to distant intracranial failure: A session-wise analysis in a histology-diverse patient cohort. <i>Neuro-Oncology</i> , 2025, 27, 854-864.	1.0	4
2	Future Directions in the Treatment of Low-Grade Gliomas. <i>Cancer Journal (Sudbury, Mass )</i> , 2025, 31, .	1.8	0
3	The role of upfront radiation therapy for brain metastases in the era of CNS-active systemic therapies: a narrative review of clinical trial design and lessons learned. <i>Journal of Neuro-Oncology</i> , 2025, 173, 11-19.	2.5	0
4	Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy in One Fraction (SMART ONE): A Multicenter, Single-Arm, Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2025, 122, 957-967.	1.5	7
5	Integrating a novel tablet-based digital neurocognitive assessment tool in brain metastases patients. <i>Journal of Neuro-Oncology</i> , 2025, 174, 121-129.	2.5	1
6	Temporospatial tumor dynamic changes in glioblastoma during radiotherapy. <i>Journal of Neuro-Oncology</i> , 2025, 174, 493-501.	2.5	1
7	Assessment of outcomes and machine Learning-based models to predict local failure risk following stereotactic radiosurgery for small brain metastases. <i>Journal of Neuro-Oncology</i> , 2025, 174, 635-643.	2.5	2
8	Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas. <i>Lancet Oncology, The</i> , 2025, 26, e436-e447.	27.4	12
9	The Rationale for Early Adjuvant Radiotherapy After Gross Total Resection of Atypical Meningioma. <i>Neurosurgery</i> , 2025, 97, 521-524.	2.0	0
10	Concurrent Lapatinib With Brain Radiation Therapy in Patients With HER2+ Breast Cancer With Brain Metastases: NRG Oncology's KROG/RTOG 1119 Phase 2 Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2024, 118, 1391-1401.	1.5	14
11	Dosimetric comparison of magnetic resonance-guided radiation therapy, intensity-modulated proton therapy and volumetric-modulated arc therapy for distal esophageal cancer. <i>Medical Dosimetry</i> , 2024, 49, 121-126.	0.9	1
12	Impact of Apolipoprotein E Genotype on Neurocognitive Function in Patients With Brain Metastases: An Analysis of NRG Oncology's RTOG 0614. <i>International Journal of Radiation Oncology Biology Physics</i> , 2024, 119, 846-857.	1.5	4
13	Accelerated Hypofractionated Magnetic Resonance Guided Adaptive Radiation Therapy for Ultracentral Lung Tumors. <i>Tomography</i> , 2024, 10, 169-180.	2.0	4
14	Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort. <i>Neuro-Oncology</i> , 2024, 26, S165-S172.	1.0	6
15	Clinical application of an institutional fractionated stereotactic radiosurgery (FSRS) program for brain metastases delivered with MRIdian's BrainTx. <i>Medical Dosimetry</i> , 2024, 49, 263-270.	0.9	2
16	An Update on H3K27M-altered Diffuse Midline Glioma: Diagnostic and Therapeutic Challenges in Clinical Practice. <i>Practical Radiation Oncology</i> , 2024, 14, 443-451.	2.7	9
17	DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology. <i>Neuro-Oncology</i> , 2024, 26, 1367-1387.	1.0	15
18	Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era. <i>Journal of Clinical Oncology</i> , 2024, 42, 2588-2598.	16.9	7

#	ARTICLE	IF	CITATIONS
19	Comparative evaluation of outcomes amongst different radiosurgery management paradigms for patients with large brain metastasis. <i>Journal of Neuro-Oncology</i> , 2024, 169, 105-117.	2.5	6
20	NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2024, 26, 1628-1637.	1.0	18
21	A Neuroradiologist's Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults. <i>American Journal of Neuroradiology</i> , 2024, 45, 1846-1856.	2.6	18
22	The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas. <i>Neuro-Oncology</i> , 2024, 26, 1839-1849.	1.0	5
23	Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy for Painful Spinal Metastases: A Comparative Analysis of Randomized Trials and Practical Considerations. <i>Practical Radiation Oncology</i> , 2024, 14, 512-521.	2.7	4
24	Surgically targeted radiation therapy versus stereotactic radiation therapy: A dosimetric comparison for brain metastasis resection cavities. <i>Brachytherapy</i> , 2024, 23, 751-760.	1.1	5
25	Radiotherapeutic advances in the management of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2024, 170, 509-520.	2.5	2
26	Initial feasibility cohort of temporally modulated pulsed proton re-irradiation (TMPPR) for recurrent high-grade intracranial malignancies. <i>Scientific Reports</i> , 2024, 14, .	3.4	0
27	Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539. <i>Neuro-Oncology</i> , 2023, 25, 137-145.	1.0	35
28	Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. <i>Neuro-Oncology</i> , 2023, 25, 339-350.	1.0	125
29	Rethinking Classification and Categorization of Resection Extent and its Impact on Patient Survival in Glioblastoma: Was Walter Dandy Ahead of His Time?. <i>Neuro-Oncology</i> , 2023, .	1.0	2
30	Dosimetric Impact of Lesion Number, Size, and Volume on Mean Brain Dose with Stereotactic Radiosurgery for Multiple Brain Metastases. <i>Cancers</i> , 2023, 15, 780.	3.8	11
31	Treatment of glioblastoma using MRIdian A3i BrainTx: Imaging and treatment workflow demonstration. <i>Medical Dosimetry</i> , 2023, 48, 127-133.	0.9	12
32	Evaluating the intracranial activity of adagrasib. <i>Translational Lung Cancer Research</i> , 2023, 12, 669-675.	2.0	1
33	Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 117, 571-580.	1.5	46
34	Accelerated hypofractionated magnetic resonance-guided adaptive radiotherapy for oligoprogressive non-small cell lung cancer. <i>Medical Dosimetry</i> , 2023, 48, 238-244.	0.9	3
35	A study on interplaner plan quality variability using a manual planning or Lightning dose optimizer approach for single brain lesions treated with the Gamma Knife Icon. <i>Journal of Applied Clinical Medical Physics</i> , 2023, 24, .	2.1	5
36	Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. <i>Cancer Discovery</i> , 2023, 13, 2370-2393.	25.1	124

#	ARTICLE	IF	CITATIONS
37	Surgically targeted radiation therapy (STaRT) for recurrent brain metastases: Initial clinical experience. <i>Brachytherapy</i> , 2023, 22, 872-881.	1.1	10
38	NRG/ROG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2023, 5, .	0.9	5
39	National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities. <i>Lancet Oncology</i> , The, 2023, 24, e344-e354.	27.4	33
40	RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. <i>Journal of Clinical Oncology</i> , 2023, 41, 5187-5199.	16.9	333
41	A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups. <i>Lancet Oncology</i> , The, 2023, 24, e438-e450.	27.4	47
42	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 585-593.	6.8	39
43	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602.	6.8	142
44	Systematic evaluation and plan quality assessment of the Leksell <sup>®</sup> gamma knife <sup>®</sup> lightning dose optimizer. <i>Medical Dosimetry</i> , 2022, 47, 70-78.	0.9	19
45	Dose-Escalated Magnetic Resonance Image <sup>®</sup> Guided Abdominopelvic Reirradiation With Continuous Intrafraction Visualization, Soft Tissue Tracking, and Automatic Beam Gating. <i>Advances in Radiation Oncology</i> , 2022, 7, 100840.	1.3	14
46	CT-guided versus MR-guided radiotherapy: Impact on gastrointestinal sparing in adrenal stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2022, 166, 101-109.	2.0	26
47	Relationship between insurance status and interhospital transfers among cancer patients in the United States. <i>BMC Cancer</i> , 2022, 22, .	2.9	4
48	Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases. <i>Frontiers in Oncology</i> , 2022, 11, .	2.6	16
49	Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 60-74.	1.5	97
50	Evaluation of the impact of pre-operative stereotactic radiotherapy on the acute changes in histopathologic and immune marker profiles of brain metastases. <i>Scientific Reports</i> , 2022, 12, .	3.4	19
51	Hospitalization rates from radiotherapy complications in the United States. <i>Scientific Reports</i> , 2022, 12, .	3.4	14
52	Evaluation of a prospective radiation oncology departmental team review process using standardized simulation directives. <i>Radiotherapy and Oncology</i> , 2022, 170, 102-110.	2.0	3
53	Association of Pretreatment Hippocampal Volume With Neurocognitive Function in Patients Treated With Hippocampal Avoidance Whole Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology/ROG 0933. <i>Advances in Radiation Oncology</i> , 2022, 7, 100859.	1.3	4
54	Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data. <i>Cancers</i> , 2022, 14, 2020.	3.8	15

#	ARTICLE	IF	CITATIONS
55	Multi-Institutional Outcomes of Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy With a Median Biologically Effective Dose of 100 Gy10 for Non-bone Oligometastases. <i>Advances in Radiation Oncology</i> , 2022, 7, 100978.	1.3	7
56	Implementation Strategies to Increase Clinical Trial Enrollment in a Community-Academic Partnership and Impact on Hispanic Representation: An Interrupted Time Series Analysis. <i>JCO Oncology Practice</i> , 2022, 18, e780-e785.	3.0	18
57	Dedicated isotropic 3-D T1 SPACE sequence imaging for radiosurgery planning improves brain metastases detection and reduces the risk of intracranial relapse. <i>Radiotherapy and Oncology</i> , 2022, 173, 84-92.	2.0	15
58	Optimizing the Radiotherapy Treatment Planning Process for Glioblastoma. <i>Neuro-Oncology Practice</i> , 2022, , .	0.9	1
59	Pulsed-Reduced Dose Rate (PRDR) Radiotherapy for Recurrent Primary Central Nervous System Malignancies: Dosimetric and Clinical Results. <i>Cancers</i> , 2022, 14, 2946.	3.8	7
60	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. <i>Journal of Clinical Oncology</i> , 2022, 40, 2539-2545.	16.9	78
61	Zero Setup Margin Mask versus Frame Immobilization during Gamma Knife® Iconâ„¢ Stereotactic Radiosurgery for Brain Metastases. <i>Cancers</i> , 2022, 14, 3392.	3.8	14
62	Access to Radiation Therapy: From Local to Global and Equality to Equity. <i>JCO Global Oncology</i> , 2022, , .	2.1	29
63	Prevalence and Inpatient Hospital Outcomes of Malignancy-Related Ascites in the United States. <i>American Journal of Hospice and Palliative Medicine</i> , 2021, 38, 47-53.	1.6	13
64	Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825). <i>Neuro-Oncology</i> , 2021, 23, 1125-1138.	1.0	37
65	Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance. <i>Neuro-Oncology Advances</i> , 2021, 3, .	0.9	22
66	Case report of visual biofeedback-driven, magnetic resonance-guided single-fraction SABR in breath hold for early stage nonâ€“small-cell lung cancer. <i>Medical Dosimetry</i> , 2021, 46, 247-252.	0.9	9
67	Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. <i>Neuro-Oncology</i> , 2021, 23, 881-893.	1.0	113
68	Novel Radiation Approaches. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 211-223.	1.4	8
69	Regression of Intracranial Meningiomas Following Treatment with Cabozantinib. <i>Current Oncology</i> , 2021, 28, 1537-1543.	3.0	8
70	Hospitalization rates for complications due to systemic therapy in the United States. <i>Scientific Reports</i> , 2021, 11, .	3.4	16
71	Meta-Analysis of Survival and Development of a Prognostic Nomogram for Malignant Pleural Mesothelioma Treated with Systemic Chemotherapy. <i>Cancers</i> , 2021, 13, 2186.	3.8	11
72	Stereotactic MR-guided online adaptive radiotherapy reirradiation (SMART reRT) for locally recurrent pancreatic adenocarcinoma: A case report. <i>Medical Dosimetry</i> , 2021, 46, 384-388.	0.9	9

#	ARTICLE	IF	CITATIONS
73	Assessment of extracranial metastatic disease in patients with brain metastases: How much effort is needed in the context of evolving survival prediction models?. <i>Radiotherapy and Oncology</i> , 2021, 159, 17-20.	2.0	7
74	Integration of Systemic Therapy and Stereotactic Radiosurgery for Brain Metastases. <i>Cancers</i> , 2021, 13, 3682.	3.8	39
75	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		73
76	Impact of MRI timing on tumor volume and anatomic displacement for brain metastases undergoing stereotactic radiosurgery. <i>Neuro-Oncology Practice</i> , 2021, 8, 674-683.	0.9	6
77	Effect of Postoperative Radiation Therapy Timing on Survival in Pediatric and Young Adult Ependymoma. <i>Advances in Radiation Oncology</i> , 2021, 6, 100691.	1.3	2
78	Cross-sectional survey of patients, caregivers, and physicians on diagnosis and treatment of brain metastases. <i>Neuro-Oncology Practice</i> , 2021, 8, 662-673.	0.9	6
79	RADI-11. Evaluating the Tissue Effects of Dose-escalated Pre-operative Stereotactic Radiotherapy for Resectable Brain Metastasis. <i>Neuro-Oncology Advances</i> , 2021, 3, iii20-iii20.	0.9	0
80	OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance. <i>Neuro-Oncology Advances</i> , 2021, 3, iii15-iii16.	0.9	0
81	Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance. <i>Discover Oncology</i> , 2021, 12, .	2.4	14
82	A Comprehensive Analysis of a Prospective Multidisciplinary Peer Review Process Before Radiation Therapy Simulation. <i>Practical Radiation Oncology</i> , 2021, 11, e366-e375.	2.7	3
83	Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. <i>Journal of Neuro-Oncology</i> , 2021, 155, 363-372.	2.5	13
84	Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis. <i>Neuro-Oncology Advances</i> , 2021, 3, .	0.9	12
85	Factors associated with unplanned readmissions and costs following resection of brain metastases in the United States. <i>Scientific Reports</i> , 2021, 11, .	3.4	7
86	High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 790-799.	1.5	176
87	Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. <i>Neuro-Oncology Advances</i> , 2020, 2, .	0.9	12
88	Radiotherapy innovations to optimize brain metastases control. <i>Neuro-Oncology</i> , 2020, 22, 1715-1717.	1.0	0
89	Inpatient Palliative Care Use Among Critically Ill Brain Metastasis Patients in the United States. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 806-812.	1.3	6
90	Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. <i>Journal of Clinical Oncology</i> , 2020, 38, 3773-3784.	16.9	393

#	ARTICLE	IF	CITATIONS
91	Effectiveness of Radiofrequency Ablation in the Treatment of Painful Osseous Metastases: A Correlation Meta-Analysis with Machine Learning Cluster Identification. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1753-1762.	1.1	18
92	A risk model for prediction of 30-day readmission rates after surgical treatment for colon cancer. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1529-1535.	1.8	3
93	Extreme hypofractionation for newly diagnosed glioblastoma: rationale, dose, techniques, and outcomes. <i>Neuro-Oncology</i> , 2020, 22, 1062-1064.	1.0	2
94	NRG/RTOG 1122: A phase 2, double-blind, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. <i>Cancer</i> , 2020, 126, 2821-2828.	4.0	38
95	Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. <i>Frontiers in Oncology</i> , 2020, 10, .	2.6	27
96	Early imaging marker of progressing glioblastoma: a window of opportunity. <i>Journal of Neuro-Oncology</i> , 2020, 148, 629-640.	2.5	4
97	Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. <i>Neuro-Oncology</i> , 2020, 22, 1359-1367.	1.0	70
98	Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 334-343.	1.5	129
99	Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. <i>Neuro-Oncology</i> , 2020, 22, 94-102.	1.0	75
100	Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 720-725.	1.5	49
101	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	1.0	965
102	Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition. <i>Acta Neuropathologica</i> , 2020, 139, 1071-1088.	9.2	81
103	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. <i>Neuro-Oncology</i> , 2020, , .	1.0	27
104	Investigating Low-Dose Thoracic Radiation as a Treatment for COVID-19 Patients to Prevent Respiratory Failure. <i>Radiation Research</i> , 2020, 194, 1.	2.1	17
105	Preoperative Vs Postoperative Radiosurgery For Resected Brain Metastases: A Review. <i>Neurosurgery</i> , 2019, 84, 19-29.	2.0	61
106	Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933. <i>Advances in Radiation Oncology</i> , 2019, 4, 579-586.	1.3	27
107	Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA). <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 39-45.	0.9	30
108	The association between BMI and BSA“temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525. <i>Neuro-Oncology Practice</i> , 2019, 6, 473-478.	0.9	7

#	ARTICLE	IF	CITATIONS
109	Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. <i>Journal of Neuro-Oncology</i> , 2019, 145, 97-105.	2.5	172
110	Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. <i>Neurosurgery</i> , 2019, 85, E607-E608.	2.0	29
111	The Complexity of Managing Large Brain Metastasis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 483-484.	1.5	8
112	Updates in the management of intradural spinal cord tumors: a radiation oncology focus. <i>Neuro-Oncology</i> , 2019, 21, 707-718.	1.0	38
113	Defining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis. <i>Anticancer Research</i> , 2019, 39, 2911-2918.	1.1	8
114	NRG brain tumor specialists consensus guidelines for glioblastoma contouring. <i>Journal of Neuro-Oncology</i> , 2019, 143, 157-166.	2.5	103
115	Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?. <i>Translational Research</i> , 2019, 208, 63-72.	4.0	13
116	Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous. <i>Radiation Oncology</i> , 2019, 14, .	2.7	28
117	Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 878-886.	1.5	10
118	MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. <i>Neuro-Oncology</i> , 2019, 21, 167-178.	1.0	276
119	Low-Grade Glioma Radiotherapy Treatment and Trials. <i>Neurosurgery Clinics of North America</i> , 2019, 30, 111-118.	1.4	76
120	Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. <i>Neurosurgery</i> , 2019, 84, 66-76.	2.0	10
121	Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. <i>Neuro-Oncology</i> , 2018, 20, 966-974.	1.0	44
122	A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. <i>Neuro-Oncology</i> , 2018, 20, 666-673.	1.0	135
123	Repeat reirradiation of the spinal cord: multi-national expert treatment recommendations. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 365-374.	2.1	22
124	Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology</i> , The, 2018, 19, e33-e42.	27.4	54
125	Control versus cognition: the changing paradigm of adjuvant therapy for resected brain metastasis. <i>Neuro-Oncology</i> , 2018, 20, 2-3.	1.0	7
126	Consolidative Whole-Brain Radiation Therapy Versus Autologous Stem Cell Transplant for Primary Central Nervous System Lymphoma: A Large Dose of Perspective and Perhaps a Lower Dose of Radiation Are in Order. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 59-60.	1.5	3

#	ARTICLE	IF	CITATIONS
127	Prognostic and predictive factors in patients with brain metastases from solid tumors: A review of published nomograms. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 13-18.	5.0	60
128	Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 38-44.	1.5	64
129	The Evolving Role of Tumor Treating Fields in Managing Glioblastoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 191-196.	1.3	67
130	ACTR-34. INTEGRATED CLINICAL EXPERIENCE WITH ONC201 IN PREVIOUSLY-TREATED H3 K27M-MUTANT GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi19-vi19.	1.0	3
131	Postoperative Management of Resected Brain Metastases: When Can Radiotherapy Be Deferred?. <i>Journal of Clinical Oncology</i> , 2018, 36, 3277-3281.	16.9	0
132	What is the evidence for the clinical value of SBRT in cancer of the cervix?. <i>Reports of Practical Oncology and Radiotherapy</i> , 2018, 23, 574-579.	1.5	16
133	Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 845-853.	1.5	25
134	Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. <i>Neuro-Oncology</i> , 2018, 20, 1652-1660.	1.0	60
135	Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study. <i>Journal of Neuro-Oncology</i> , 2018, 140, 341-349.	2.5	17
136	Recent advances in managing brain metastasis. <i>F1000Research</i> , 2018, 7, 1772.	0.5	91
137	An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. <i>Neuro-Oncology</i> , 2017, , now208.	1.0	119
138	A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 820-828.	1.5	35
139	The role of radiation in treating glioblastoma: here to stay. <i>Journal of Neuro-Oncology</i> , 2017, 134, 479-485.	2.5	34
140	Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage AI disease. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 515-524.	2.1	13
141	Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, 376-381.	2.0	96
142	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. <i>Neuro-Oncology</i> , 2017, 19, 1119-1126.	1.0	124
143	Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation. <i>Journal of Neuro-Oncology</i> , 2017, 134, 331-338.	2.5	25
144	Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 362-371.	1.5	88

#	ARTICLE	IF	CITATIONS
145	Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 228-235.	1.5	65
146	Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. <i>Journal of Neuro-Oncology</i> , 2017, 136, 79-86.	2.5	29
147	Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, , 75-81.	4.5	20
148	Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 644-664.	1.4	61
149	Clinical ramifications of "genomic staging" of low-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2016, 129, 195-199.	2.5	14
150	Updates in the management of brain metastases. <i>Neuro-Oncology</i> , 2016, 18, 1043-1065.	1.0	251
151	A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. <i>Cancer</i> , 2016, 122, 1483-1501.	4.0	195
152	Proton therapy for paediatric CNS tumours "improving treatment-related outcomes. <i>Nature Reviews Neurology</i> , 2016, 12, 334-345.	28.6	62
153	Clinical Outcomes and Toxicity of Proton Radiotherapy for Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 145-154.	2.3	62
154	Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. <i>New England Journal of Medicine</i> , 2016, 374, 1344-1355.	34.6	975
155	Neural stem cells, the subventricular zone and radiotherapy: implications for treating glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 128, 207-216.	2.5	32
156	The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 406-413.	1.5	93
157	Proton radiotherapy for gynecologic neoplasms. <i>Acta Oncologica</i> , 2016, 55, 1257-1265.	1.8	26
158	Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma"An Easy Question Turned Difficult: Treat the Scan or the Patient?. <i>Journal of Clinical Oncology</i> , 2016, 34, 1281-1282.	16.9	6
159	Glioblastoma: Radiation treatment margins, how small is large enough?. <i>Practical Radiation Oncology</i> , 2016, 6, 298-305.	2.7	47
160	International Medical Graduates in Radiation Oncology: Historical Trends and Comparison With Other Medical Specialties. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1102-1106.	1.5	9
161	Pathologic deposition of non-amyloid immunoglobulin in the brain leading to mass effect and neurological deficits. <i>Journal of Clinical Neuroscience</i> , 2016, 30, 143-145.	1.6	4
162	Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, 75-81.	4.5	4

#	ARTICLE	IF	CITATIONS
163	Context for Protons as Adjunctive Therapy in Neovascular Age-Related Macular Degeneration: A Review. <i>International Journal of Particle Therapy</i> , 2016, 2, 555-569.	1.9	0
164	ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA. <i>Neuro-Oncology</i> , 2015, 17, v6.2-v6.	1.0	2
165	BMET-20RTOG1119 PHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASIS FROM Her2-POSITIVE BREAST CANCER: A COLLABORATIVE STUDY OF NRG AND KROG (NCT01622868). <i>Neuro-Oncology</i> , 2015, 17, v49.2-v49.	1.0	0
166	RTRB-03SHORT DELAY IN INITIATION OF RADIOTHERAPY WITH CONCURRENT CHEMOTHERAPY FOR GLIOBLASTOMA: A SECONDARY ANALYSIS OF NRG ONCOLOGY/RTOG 0525 AND 0825. <i>Neuro-Oncology</i> , 2015, 17, v195.3-v195.	1.0	0
167	OP02ADOLESCENT/YOUNG ADULT MEDULLOBLASTOMA: TIME FOR A CHANGE IN MANAGEMENT STRATEGY. <i>Neuro-Oncology</i> , 2015, 17, viii16.2-viii16.	1.0	0
168	Whole-Brain Radiotherapy and Stereotactic Radiosurgery in Brain Metastases: What Is the Evidence?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e99-e104.	4.5	14
169	Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients. <i>Clinical Lung Cancer</i> , 2015, 16, 413-430.	2.8	49
170	Response assessment criteria for brain metastases: proposal from the RANO group. <i>Lancet Oncology</i> , The, 2015, 16, e270-e278.	27.4	957
171	ATCT-29INVESTIGATING THE EFFECT OF REIRRADIATION OR SYSTEMIC THERAPY IN PATIENTS WITH GBM AFTER TUMOR PROGRESSION: A SECONDARY ANALYSIS OF THE NRG ONCOLOGY/RTOG 0525. <i>Neuro-Oncology</i> , 2015, 17, v8.1-v8.	1.0	0
172	ATCT-08THE IMPACT OF EXTENDED ADJUVANT TEMOZOLOMIDE IN NEWLY-DIAGNOSED GLIOBLASTOMA: A SECONDARY ANALYSIS OF EORTC AND NRG ONCOLOGY/RTOG. <i>Neuro-Oncology</i> , 2015, 17, v2.4-v2.	1.0	3
173	Society for Neuro-Oncology 2014 annual meeting updates on central nervous system metastases. <i>Neuro-Oncology Practice</i> , 2015, 2, 57-61.	0.9	1
174	ATCT-12RESULTS OF NRG ONCOLOGY/RTOG 9813- A PHASE III RANDOMIZED STUDY OF RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) VERSUS RT AND NITROSOUREA (NU) THERAPY FOR ANAPLASTIC ASTROCYTOMA (AA). <i>Neuro-Oncology</i> , 2015, 17, v3.4-v3.	1.0	1
175	Real-Time Pretreatment Review Limits Unacceptable Deviations on a Cooperative Group Radiation Therapy Technique Trial: Quality Assurance Results of RTOG 0933. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 564-570.	1.5	33
176	The controversy surrounding the use of whole-brain radiotherapy in brain metastases patients. <i>Neuro-Oncology</i> , 2015, 17, 919-923.	1.0	25
177	Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study. <i>Journal of Neuro-Oncology</i> , 2015, 122, 409-417.	2.5	96
178	Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). <i>Neuro-Oncology</i> , 2015, 17, 992-998.	1.0	133
179	Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. <i>Journal of Neuro-Oncology</i> , 2015, 124, 413-420.	2.5	31
180	Management of solitary and multiple brain metastases from breast cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2015, 36, 87-93.	0.5	20

#	ARTICLE	IF	CITATIONS
181	Stereotactic Radiosurgery for Glioblastoma. <i>Cureus</i> , 2015, , .	0.6	35
182	Radiation-induced brain damage, impact of Michael Robbins's™ work and the need for predictive biomarkers. <i>International Journal of Radiation Biology</i> , 2014, 90, 742-752.	2.2	17
183	Prophylactic Cranial Irradiation: Recent Outcomes and Innovations. <i>CNS Oncology</i> , 2014, 3, 219-230.	2.4	14
184	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. <i>Neuro-Oncology</i> , 2014, 16, 567-578.	1.0	147
185	Bevacizumab for Newly Diagnosed Glioblastoma. <i>New England Journal of Medicine</i> , 2014, 370, 2048-2049.	34.6	99
186	Reirradiation for Locoregionally Recurrent Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 70-76.	1.3	40
187	It Is Time to Reevaluate the Management of Patients With Brain Metastases. <i>Neurosurgery</i> , 2014, 75, 1-9.	2.0	26
188	A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma. <i>New England Journal of Medicine</i> , 2014, 370, 699-708.	34.6	2,591
189	Potential of glyburide to reduce intracerebral edema in brain metastases. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 379-388.	2.9	10
190	Strategies to Prevent Brain Metastasis in High-Risk Non-Small-Cell Lung Cancer: Lessons Learned From a Randomized Study of Maintenance Temozolomide Versus Observation. <i>Clinical Lung Cancer</i> , 2014, 15, 433-440.	2.8	16
191	Brain metastasis and treatment. <i>F1000prime Reports</i> , 2014, 6, .	4.1	52
192	The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. <i>Journal of Neuro-Oncology</i> , 2013, 112, 467-472.	2.5	152
193	Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. <i>Neuro-Oncology</i> , 2013, 15, 1429-1437.	1.0	869
194	RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 880-884.	1.5	62
195	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. <i>Lancet Oncology</i> , The, 2013, 14, e396-e406.	27.4	123
196	Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. <i>Lancet Oncology</i> , The, 2013, 14, e407-e416.	27.4	129
197	Hippocampal Dosimetry Predicts Neurocognitive Function Impairment After Fractionated Stereotactic Radiotherapy for Benign or Low-Grade Adult Brain Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 348-354.	1.5	339
198	A Roundtable Discussion on the Clinical Challenges and Options for the Treatment of Glioblastoma: Introducing a Novel Modality, TTFIELDS. <i>Seminars in Oncology</i> , 2013, 40, S2-S4.	1.9	5

#	ARTICLE	IF	CITATIONS
199	A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1312-1318.	1.5	263
200	Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM). <i>Biomarker Research</i> , 2013, 1, .	9.0	5
201	Pseudoprogression after glioma therapy: a comprehensive review. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 389-403.	2.9	103
202	Molecular Profiling in Non-Small Cell Lung Cancer: A Step Toward Personalized Medicine. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 481-491.	2.4	58
203	American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for the Performance of Stereotactic Radiosurgery (SRS). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 310-315.	1.3	106
204	Using Intensity-Modulated Radiotherapy to Spare the Kidney in a Patient with Seminoma and a Solitary Kidney: A Case Report. <i>Tumori</i> , 2013, 99, e38-e42.	1.4	5
205	Single institution experience treating 104 vestibular schwannomas with fractionated stereotactic radiation therapy or stereotactic radiosurgery. <i>Journal of Neuro-Oncology</i> , 2013, 116, 187-193.	2.5	74
206	Orbital metastasis of pituitary growth hormone secreting carcinoma causing lateral gaze palsy. , 2013, 4, 59.		10
207	Treatment of Wilms's Tumour. <i>Drugs</i> , 2012, 42, 766-780.	11.4	9
208	Brain metastases. <i>Current Opinion in Supportive and Palliative Care</i> , 2012, 6, 85-90.	1.8	15
209	Cognitive function testing in adult brain tumor trials: lessons from a comprehensive review. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 655-667.	2.5	16
210	Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. <i>Neuro-Oncology</i> , 2012, 14, 1511-1518.	1.0	105
211	Integrated phase II/III clinical trials in oncology: A case study. <i>Clinical Trials</i> , 2012, 9, 741-747.	1.8	7
212	Differential Sensitivity of Glioma- versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors. <i>Cancer Discovery</i> , 2012, 2, 458-471.	25.1	330
213	A nomogram for individualized estimation of survival among patients with brain metastasis. <i>Neuro-Oncology</i> , 2012, 14, 910-918.	1.0	135
214	Hippocampal Dosimetry Predicts Neurocognitive Function Impairment After Fractionated Stereotactic Radiotherapy for Benign or Low-Grade Adult Brain Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e487-e493.	1.5	213
215	Intracranial relapse rates and patterns, and survival trends following post-resection cavity radiosurgery for patients with single intracranial metastases. <i>Journal of Neuro-Oncology</i> , 2012, 108, 141-146.	2.5	29
216	Brain metastases: pathobiology and emerging targeted therapies. <i>Acta Neuropathologica</i> , 2012, 123, 205-222.	9.2	186

#	ARTICLE	IF	CITATIONS
217	A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806). <i>Journal of Neuro-Oncology</i> , 2012, 111, 33-39.	2.5	15
218	Estimated radiation pneumonitis risk after photon versus proton therapy alone or combined with chemotherapy for lung cancer. <i>Acta Oncologica</i> , 2011, 50, 772-776.	1.8	26
219	An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR-Dependent Pathway. <i>Cancer Discovery</i> , 2011, 1, 442-456.	25.1	405
220	Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma. <i>Medical Hypotheses</i> , 2011, 76, 410-413.	0.7	15
221	In response to "The distribution of brain metastases in the perihippocampal region (Regarding Gondi et al) <i>Journal of Neuro-Oncology</i> , 2011, 111, 107-114.	2.0	3
222	Dosimetric comparison of left-sided whole breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy, and topotherapy. <i>Radiotherapy and Oncology</i> , 2011, 100, 241-246.	2.0	158
223	Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 623-630.	1.5	225
224	A Phase I Trial of Tipifarnib With Radiation Therapy, With and Without Temozolomide, for Patients With Newly Diagnosed Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1422-1427.	1.5	29
225	Reply to Drs. Mulvenna and Holt. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1194-1195.	1.5	0
226	Combined Modality Approaches in the Management of Adult Glioblastoma. <i>Frontiers in Oncology</i> , 2011, 1, .	2.6	8
227	Stereotactic Body Radiation Therapy in Non-Small-Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 432-441.	1.3	14
228	A Comparison of Helical Tomotherapy to Circular Collimator-Based Linear-Accelerator Radiosurgery for the Treatment of Brain Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 388-394.	1.3	17
229	Age as an independent prognostic factor in patients with glioblastoma: a radiation therapy oncology group and American College of Surgeons National Cancer Data Base comparison. <i>Journal of Neuro-Oncology</i> , 2011, 104, 351-356.	2.5	44
230	Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of brain metastases: a multi-institutional phase II trial. <i>Journal of Neuro-Oncology</i> , 2011, 105, 301-308.	2.5	19
231	Presentation, patterns of care, and survival in patients with brain metastases. <i>Cancer</i> , 2011, 117, 2505-2512.	4.0	183
232	In Response to Dr. Knisely and Colleagues. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 958.	1.5	1
233	Intensity-Modulated Radiotherapy Might Increase Pneumonitis Risk Relative to Three-Dimensional Conformal Radiotherapy in Patients Receiving Combined Chemotherapy and Radiotherapy: A Modeling Study of Dose Dumping. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 893-899.	1.5	32
234	Role of isocitrate dehydrogenase in glioma. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1399-1409.	2.9	15

#	ARTICLE	IF	CITATIONS
235	Clinical trial end points for high-grade glioma: the evolving landscape. <i>Neuro-Oncology</i> , 2011, 13, 353-361.	1.0	109
236	Novel insights into the management of brain metastases. <i>Current Opinion in Neurology</i> , 2010, 23, 556-562.	3.7	19
237	Fractionated radiotherapy for intracranial meningiomas. <i>Journal of Neuro-Oncology</i> , 2010, 99, 349-356.	2.5	22
238	Opportunities for clinical research in meningioma. <i>Journal of Neuro-Oncology</i> , 2010, 99, 417-422.	2.5	26
239	Angiogenic Blockade and Radiotherapy in Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 188-193.	1.5	48
240	Hippocampal-Sparing Whole-Brain Radiotherapy: A "How-To" Technique Using Helical Tomotherapy and Linear Accelerator-Based Intensity-Modulated Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1244-1252.	1.5	356
241	Treatment-Related Pneumonitis and Acute Esophagitis in Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy and Helical Tomotherapy: In Regard to Song et Al.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1281.	1.5	0
242	PROOF OF PRINCIPLE OF OCULAR SPARING IN DOGS WITH SINONASAL TUMORS TREATED WITH INTENSITY-MODULATED RADIATION THERAPY. <i>Veterinary Radiology and Ultrasound</i> , 2010, 51, 561-570.	1.3	73
243	A multigene predictor of outcome in glioblastoma. <i>Neuro-Oncology</i> , 2010, 12, 49-57.	1.0	353
244	Current Treatment Strategies for Brain Metastasis and Complications From Therapeutic Techniques. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 398-407.	1.3	65
245	Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). <i>Neuro-Oncology</i> , 2010, 12, 855-861.	1.0	204
246	Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: Safety profile for RTOG 0933. <i>Radiotherapy and Oncology</i> , 2010, 95, 327-331.	2.0	181
247	Why avoid the hippocampus? A comprehensive review. <i>Radiotherapy and Oncology</i> , 2010, 97, 370-376.	2.0	363
248	Current practices of driving restriction implementation for patients with brain tumors. <i>Journal of Neuro-Oncology</i> , 2010, 103, 641-647.	2.5	23
249	Motexafin gadolinium: a novel radiosensitizer for brain tumors. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2171-2180.	2.1	15
250	The Impact of Hybrid PET-CT Scan on Overall Oncologic Management, with a Focus on Radiotherapy Planning: A Prospective, Blinded Study. <i>Technology in Cancer Research and Treatment</i> , 2009, 8, 149-158.	2.3	33
251	EGFR Signaling Through an Akt-SREBP-1-Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antiplogenic Therapy. <i>Science Signaling</i> , 2009, 2, .	5.4	312
252	On the Estimation of the Location of the Hippocampus in the Context of Hippocampal Avoidance Whole Brain Radiotherapy Treatment Planning. <i>Technology in Cancer Research and Treatment</i> , 2009, 8, 425-432.	2.3	12

#	ARTICLE	IF	CITATIONS
253	Prognostic indices for brain metastases – usefulness and challenges. Radiation Oncology, 2009, 4, .	2.7	98
254	Phase I Three-Dimensional Conformal Radiation Dose Escalation Study in Newly Diagnosed Glioblastoma: Radiation Therapy Oncology Group Trial 98-03. International Journal of Radiation Oncology Biology Physics, 2009, 73, 699-708.	1.5	97
255	Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Non-Small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III Trial. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1069-1076.	1.5	169
256	Radiation Techniques in Neuro-Oncology. Neurotherapeutics, 2009, 6, 487-499.	6.1	14
257	A Comprehensive Assessment by Tumor Site of Patient Setup Using Daily MVCT Imaging From More Than 3,800 Helical Tomotherapy Treatments. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1260-1269.	1.5	93
258	The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2009, 96, 85-96.	2.5	131
259	The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2009, 96, 97-102.	2.5	131
260	The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2009, 96, 103-114.	2.5	322
261	The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. Journal of Neuro-Oncology, 2009, 96, 115-142.	2.5	49
262	The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2009, 96, 17-32.	2.5	288
263	The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2009, 96, 33-43.	2.5	385
264	The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2009, 96, 71-83.	2.5	148
265	The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2009, 96, 45-68.	2.5	477
266	The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group. Radiation Oncology, 2008, 3, .	2.7	45
267	Dose Coverage Beyond the Gross Tumor Volume for Various Stereotactic Body Radiotherapy Planning Techniques Reporting Similar Control Rates for Stage I Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1597-1603.	1.5	22
268	Prospective Evaluation of Quality of Life and Neurocognitive Effects in Patients With Multiple Brain Metastases Receiving Whole-Brain Radiotherapy With or Without Thalidomide on Radiation Therapy Oncology Group (RTOG) Trial 0118. International Journal of Radiation Oncology Biology Physics, 2008, 71, 71-78.	1.5	88
269	A Phase III Study of Conventional Radiation Therapy Plus Thalidomide Versus Conventional Radiation Therapy for Multiple Brain Metastases (RTOG 0118). International Journal of Radiation Oncology Biology Physics, 2008, 71, 79-86.	1.5	92
270	Relationship Between Neurocognitive Function and Quality of Life After Whole-Brain Radiotherapy in Patients With Brain Metastasis. International Journal of Radiation Oncology Biology Physics, 2008, 71, 64-70.	1.5	275

#	ARTICLE	IF	CITATIONS
271	Correlation of O <sup>6</sup> -Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity. <i>Journal of Clinical Oncology</i> , 2008, 26, 4189-4199.	16.9	775
272	Dose Escalated, Hypofractionated Radiotherapy Using Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: Preliminary Results of a Risk-Stratified Phase I Dose Escalation Study. <i>Technology in Cancer Research and Treatment</i> , 2008, 7, 441-447.	2.3	65
273	Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium. <i>Neuro-Oncology</i> , 2008, 10, 631-642.	1.0	30
274	Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase I study. <i>Neuro-Oncology</i> , 2008, 10, 752-758.	1.0	50
275	Improvement, Clinical Course, and Quality of Life After Palliative Radiotherapy for Recurrent Glioblastoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 300-305.	1.3	100
276	A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. <i>Journal of Neuro-Oncology</i> , 2008, 91, 183-189.	2.5	75
277	Resection versus radiosurgery for patients with brain metastases. <i>Future Oncology</i> , 2007, 3, 95-102.	2.3	12
278	Motexafin gadolinium: a novel radiosensitizer for brain tumors. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 785-794.	2.5	24
279	In Reply. <i>Journal of Clinical Oncology</i> , 2007, 25, 4024-4025.	16.9	3
280	Megavoltage Computed Tomography. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 617-623.	1.3	31
281	Regression After Whole-Brain Radiation Therapy for Brain Metastases Correlates With Survival and Improved Neurocognitive Function. <i>Journal of Clinical Oncology</i> , 2007, 25, 1260-1266.	16.9	318
282	Motexafin gadolinium in the treatment of brain metastases. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 351-359.	2.1	31
283	Advances in Radiation Therapy for Brain Tumors. <i>Neurologic Clinics</i> , 2007, 25, 1005-1033.	2.6	26
284	Therapeutic management of metastatic brain tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 61, 70-78.	5.0	39
285	Distribution of Brain Metastases in Relation to the Hippocampus: Implications for Neurocognitive Functional Preservation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 971-977.	1.5	183
286	Whole Brain Radiotherapy With Hippocampal Avoidance and Simultaneously Integrated Brain Metastases Boost: A Planning Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 589-597.	1.5	183
287	Impact of molecular profiling on clinical trial design for glioblastoma. <i>Current Oncology Reports</i> , 2007, 9, 71-79.	4.2	9
288	Comparison of linac based fractionated stereotactic radiotherapy and tomotherapy treatment plans for skull-base tumors. <i>Radiotherapy and Oncology</i> , 2006, 78, 313-321.	2.0	55

#	ARTICLE	IF	CITATIONS
289	Whole-Brain Radiotherapy in the Management of Brain Metastasis. <i>Journal of Clinical Oncology</i> , 2006, 24, 1295-1304.	16.9	452
290	Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 99-111.	5.0	32
291	Integral radiation dose to normal structures with conformal external beam radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 962-967.	1.5	159
292	Helical tomotherapy as a means of administering total or partial scalp irradiation: In regards to Bedford et al. ( <i>Int J Radiat Oncol Biol Phys</i> 2005;62:1549-1558). <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1288-1289.	1.5	7
293	Tumor volume changes on serial imaging with megavoltage CT for non-small-cell lung cancer during intensity-modulated radiotherapy: How reliable, consistent, and meaningful is the effect?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 135-141.	1.5	111
294	In response to Dr. Peñagarcano. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1274-1275.	1.5	1
295	Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon- $\gamma$ for supratentorial glioblastoma: Results of RTOG 9710. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 818-824.	1.5	52
296	Tomotherapy and Other Innovative IMRT Delivery Systems. <i>Seminars in Radiation Oncology</i> , 2006, 16, 199-208.	2.7	73
297	Feasibility report of image guided stereotactic body radiotherapy (IG-SBRT) with tomotherapy for early stage medically inoperable lung cancer using extreme hypofractionation. <i>Acta Oncologica</i> , 2006, 45, 890-896.	1.8	73
298	Clinical Implementation of Adaptive Helical Tomotherapy: A Unique Approach to Image-Guided Intensity Modulated Radiotherapy. <i>Technology in Cancer Research and Treatment</i> , 2006, 5, 465-479.	2.3	86
299	Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-00211. <i>Neuro-Oncology</i> , 2006, 8, 47-52.	1.0	57
300	Linear Accelerator Radiosurgery for Trigeminal Neuralgia. <i>Neurosurgery</i> , 2005, 57, 1193-1200.	2.0	48
301	The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 779-788.	1.5	263
302	In response to Drs. Vordermark and Kroll. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 297.	1.5	0
303	In reply to Dr. Kondziolka et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 615-616.	1.5	2
304	The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 37-46.	1.5	335
305	The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 47-55.	1.5	167
306	Patterns of treatment failure in infants with primitive neuroectodermal tumors who were treated on CCG-921: A phase III combined modality study. <i>Pediatric Blood and Cancer</i> , 2005, 45, 676-682.	1.3	19

#	ARTICLE	IF	CITATIONS
307	Current Strategies in Whole-brain Radiation Therapy for Brain Metastases. <i>Neurosurgery</i> , 2005, 57, S4-33.	2.0	42
308	Are gadolinium contrast agents suitable for gadolinium neutron capture therapy?. <i>Neurological Research</i> , 2005, 27, 387-398.	1.5	65
309	Current Management of Brain Metastases, With a Focus on Systemic Options. <i>Journal of Clinical Oncology</i> , 2005, 23, 6207-6219.	16.9	359
310	Phase II Study of Fenretinide (NSC 374551) in Adults With Recurrent Malignant Gliomas: A North American Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 4282-4289.	16.9	83
311	Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. <i>Neuro-Oncology</i> , 2004, 6, 44-54.	1.0	75
312	Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 157-165.	16.9	559
313	Treatment of malignant gliomas: radiotherapy, chemotherapy and integration of new targeted agents. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 691-703.	2.9	18
314	Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. <i>Neuro-Oncology</i> , 2004, 6, 96-103.	1.0	56
315	Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. <i>Neuro-Oncology</i> , 2004, 6, 33-37.	1.0	58
316	O 6-Benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. <i>Neuro-Oncology</i> , 2004, 6, 28-32.	1.0	33
317	Management of brain metastases. <i>Seminars in Oncology</i> , 2004, 31, 693-701.	1.9	106
318	Megavoltage Computed Tomography Imaging: A Potential Tool to Guide and Improve the Delivery of Thoracic Radiation Therapy. <i>Clinical Lung Cancer</i> , 2004, 5, 303-306.	2.8	48
319	Patterns of failure in supratentorial primitive neuroectodermal tumors treated in Children's Cancer Group Study 921, a phase III combined modality study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 204-213.	1.5	32
320	Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 1346-1352.	1.5	83
321	Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 1107-1115.	1.5	18
322	Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 853-860.	1.5	563
323	A challenge to traditional radiation oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1241-1256.	1.5	285
324	The utility of megavoltage computed tomography images from a helical tomotherapy system for setup verification purposes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1639-1644.	1.5	140

#	ARTICLE	IF	CITATIONS
325	Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations. <i>Current Problems in Cancer</i> , 2004, 28, 7-40.	2.0	17
326	Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. <i>Lancet</i> , The, 2004, 363, 1665-1672.	62.3	2,363
327	Title is missing!. <i>Investigational New Drugs</i> , 2003, 21, 429-433.	2.5	6
328	Combined modality treatment for central nervous system malignancies. <i>Seminars in Oncology</i> , 2003, 30, 11-22.	1.9	15
329	Clinical promise tempered by reality in the delivery of combined chemoradiation for common solid tumors. <i>Seminars in Radiation Oncology</i> , 2003, 13, 3-12.	2.7	20
330	Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases. <i>Journal of Clinical Oncology</i> , 2003, 21, 2529-2536.	16.9	456
331	Gentlemen (and Ladies), Choose your Weapons: Gamma Knife vs. Linear Accelerator Radiosurgery. <i>Technology in Cancer Research and Treatment</i> , 2003, 2, 79-85.	2.3	37
332	A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: First report of the Children's Cancer Group-0952. <i>Neuro-Oncology</i> , 2003, 5, 8-13.	1.0	40
333	Reduction in Radiation Dose to Lung and Other Normal Tissues Using Helical Tomotherapy to Treat Lung Cancer, in Comparison to Conventional Field Arrangements. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 70-78.	1.3	81
334	Title is missing!. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 273-279.	1.3	13
335	Neurocognitive and Functional Assessment of Patients With Brain Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 273-279.	1.3	71
336	Helical Tomotherapy: An Innovative Technology and Approach to Radiation Therapy. <i>Technology in Cancer Research and Treatment</i> , 2002, 1, 311-316.	2.3	159
337	Fractionated Stereotactic Radiotherapy: A Short Review. <i>Technology in Cancer Research and Treatment</i> , 2002, 1, 153-172.	2.3	26
338	Lead-In Phase to Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation for Patients With Brain Metastases: Centralized Assessment of Magnetic Resonance Imaging, Neurocognitive, and Neurologic End Points. <i>Journal of Clinical Oncology</i> , 2002, 20, 3445-3453.	16.9	143
339	A phase II trial of thymidine and carboplatin for recurrent malignant glioma: A North American Brain Tumor Consortium Study. <i>Neuro-Oncology</i> , 2002, 4, 109-114.	1.0	47
340	Composite sequential arterial reconstruction for limb salvage. <i>Journal of Vascular Surgery</i> , 2002, 36, 325-329.	1.8	20
341	Participatory evaluation of reproductive health care quality in developing countries. <i>Social Science and Medicine</i> , 2002, 55, 269-282.	4.1	47
342	Acquired cell-mediated protection in rainbow trout, <i>Oncorhynchus mykiss</i> , against the haemoflagellate, <i>Cryptobia salmositica</i> . <i>Parasitology Research</i> , 2002, 88, 956-962.	1.7	27

#	ARTICLE	IF	CITATIONS
343	Retrospective vs. randomized data: the prevalence of bias. in response to Drs. Millar and Laperriere. International Journal of Radiation Oncology Biology Physics, 2002, 53, 252-253.	1.5	0
344	A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. International Journal of Radiation Oncology Biology Physics, 2002, 53, 519-526.	1.5	522
345	What is the appropriate primary end point for clinical trials for patients with brain metastases? In Response to Drs. Burri and Asher. International Journal of Radiation Oncology Biology Physics, 2002, 53, 1394.	1.5	4
346	Antibiogram Pattern of Salmonella Species Causing Bacteraemia/Septicaemia in a Teaching Hospital. Journal of Infection, 2002, 45, 133.	2.8	0
347	Pornography in Usenet: A Study of 9,800 Randomly Selected Images. Cyberpsychology, Behavior and Social Networking, 2001, 4, 695-703.	3.0	43
348	Multicenter Phase Ib/II Trial of the Radiation Enhancer Motexafin Gadolinium in Patients With Brain Metastases. Journal of Clinical Oncology, 2001, 19, 2074-2083.	16.9	128
349	Multiple daily fractionation radiotherapy schedules in lung cancer. Current Oncology Reports, 2001, 3, 179-184.	4.2	4
350	A new approach to dose escalation in non-small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2001, 49, 23-33.	1.5	242
351	Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. International Journal of Radiation Oncology Biology Physics, 2001, 50, 1199-1206.	1.5	37
352	A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants. Cancer, 2001, 91, 417-422.	4.0	95
353	Assessment of patient-independent intrinsic error for a noninvasive frame for fractionated stereotactic radiotherapy. International Journal of Cancer, 2001, 96, 320-325.	4.3	15
354	Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. International Journal of Radiation Oncology Biology Physics, 2001, 51, 426-434.	1.5	265
355	Radiotherapy for brain tumors. Current Oncology Reports, 2000, 2, 438-444.	4.2	13
356	The Contemporary Role of Radiation Therapy in the Management of Lung Cancer. Surgical Oncology Clinics of North America, 2000, 9, 539-561.	1.5	4
357	Pilot and Safety Trial of Carboplatin, Paclitaxel, and Thalidomide in Advanced Non-small-Cell Lung Cancer. Clinical Lung Cancer, 2000, 2, 48-52.	2.8	25
358	Phase II Study of Phenylacetate in Patients With Recurrent Malignant Glioma: A North American Brain Tumor Consortium Report. Journal of Clinical Oncology, 1999, 17, 984-984.	16.9	71
359	Radiosurgery for Brain Metastases. Neurosurgery Clinics of North America, 1999, 10, 337-350.	1.4	35
360	Title is missing!. Journal of Radiosurgery, 1999, 2, 119-125.	0.1	13

#	ARTICLE	IF	CITATIONS
361	Title is missing!. Journal of Radiosurgery, 1999, 2, 153-161.	0.1	3
362	Development of a Unique Phantom to Assess the Geometric Accuracy of Magnetic Resonance Imaging for Stereotactic Localization. Neurosurgery, 1999, 45, 1423-1431.	2.0	69
363	Stereotactic Irradiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 143-146.	1.3	27
364	The Status of Stereotactic Radiosurgery for Cerebral Metastases in 1998. Journal of Radiosurgery, 1998, 1, 17-30.	0.1	11
365	A cost-effectiveness and cost-utility analysis of radiosurgery vs. resection for single-brain metastases. International Journal of Radiation Oncology Biology Physics, 1997, 39, 445-454.	1.5	200
366	The effect of M-stage on patterns of failure in posterior fossa primitive neuroectodermal tumors treated on CCG-921: A phase III study in a high-risk patient population. International Journal of Radiation Oncology Biology Physics, 1997, 38, 469-475.	1.5	41
367	214 Endobronchial and endoesophageal high dose rate brachytherapy for malignant airway and digestive tract obstructions. International Journal of Radiation Oncology Biology Physics, 1997, 39, 123.	1.5	0
368	Thorotrast-associated Oropharyngeal Hemorrhage: Treatment by Means of Carotid Occlusion with Use of Flow Arrest and Fibered Coils. Journal of Vascular and Interventional Radiology, 1996, 7, 709-712.	1.1	4
369	Localized 2DJ-resolved H MR spectroscopy of human brain tumors in vivo. Journal of Magnetic Resonance Imaging, 1996, 6, 453-459.	3.4	91
370	Manpower issues and training program directions in radiation oncology. International Journal of Radiation Oncology Biology Physics, 1996, 34, 970.	1.5	0
371	A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. International Journal of Radiation Oncology Biology Physics, 1996, 35, 27-35.	1.5	525
372	The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation. Journal of Neuro-Oncology, 1996, 30, .	2.5	49
373	Linear accelerator configurations for radiosurgery. Seminars in Radiation Oncology, 1995, 5, 203-212.	2.7	17
374	The physical, biologic, and clinical basis of radiosurgery. Current Problems in Cancer, 1995, 19, 270-328.	2.0	34
375	Radiosurgery in the initial management of malignant gliomas: Survival comparison with the RTOG recursive partitioning analysis. International Journal of Radiation Oncology Biology Physics, 1995, 32, 931-941.	1.5	178
376	Stereotactic radiosurgery improves survival in malignant gliomas compared with the RTOG recursive partitioning analysis. International Journal of Radiation Oncology Biology Physics, 1994, 30, 164-165.	1.5	7
377	Stereotactic radiosurgery for glioblastoma multiforme: Report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. International Journal of Radiation Oncology Biology Physics, 1994, 30, 541-549.	1.5	151
378	Consensus statement on stereotactic radiosurgery quality improvement. International Journal of Radiation Oncology Biology Physics, 1994, 28, 527-530.	1.5	26

#	ARTICLE	IF	CITATIONS
379	Thoracic volume radiation sparing following endobronchial brachytherapy: A quantitative analysis. International Journal of Radiation Oncology Biology Physics, 1993, 25, 703-707.	1.5	23
380	Treatment of arteriovenous malformations with stereotactic radiosurgery employing both magnetic resonance angiography and standard angiography as a database. International Journal of Radiation Oncology Biology Physics, 1993, 25, 309-313.	1.5	55
381	Inguinofemoral radiation of NO,N1 vulvar cancer may be equivalent to lymphadenectomy if proper radiation technique is used. International Journal of Radiation Oncology Biology Physics, 1993, 27, 963-967.	1.5	80
382	Consensus guidelines for high dose rate remote brachytherapy in cervical, endometrial, and endobronchial tumors*. International Journal of Radiation Oncology Biology Physics, 1993, 27, 1241-1244.	1.5	53
383	Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. Journal of Neuro-Oncology, 1993, 15, 57-66.	2.5	37
384	A Retrospective Review of Nodal Treatment for Vulvar Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1993, 16, 38-42.	1.3	39
385	Meningeal hemangiopericytoma: defining the role for radiation therapy. Journal of Neuro-Oncology, 1992, 14, .	2.5	71
386	Sequential comparison of low dose rate and hyperfractionated high dose rate endobronchial radiation for malignant airway occlusion. International Journal of Radiation Oncology Biology Physics, 1992, 23, 133-139.	1.5	64
387	Endobronchial brachytherapy: Wither prescription point. International Journal of Radiation Oncology Biology Physics, 1992, 23, 251.	1.5	1
388	A three-dimensional volume visualization package applied to stereotactic radiosurgery treatment planning. International Journal of Radiation Oncology Biology Physics, 1991, 21, 491-500.	1.5	46
389	Early changes in tumor metabolism after treatment: The effects of stereotactic radiotherapy. International Journal of Radiation Oncology Biology Physics, 1991, 20, 1053-1060.	1.5	60
390	Effect of Endobronchial Radiation Therapy on Malignant Bronchial Obstruction. Chest, 1990, 97, 662-665.	1.0	46
391	Monte Carlo and convolution dosimetry for stereotactic radiosurgery. International Journal of Radiation Oncology Biology Physics, 1990, 19, 1027-1035.	1.5	49
392	90Y $\hat{A}$ B72.3 Against pancreatic cancer: Dosimetric and biological analysis. International Journal of Radiation Oncology Biology Physics, 1990, 19, 627-631.	1.5	11
393	Minimization of small bowel volume within treatment fields utilizing customized $\hat{A}$ œbelly boards $\hat{A}$ . International Journal of Radiation Oncology Biology Physics, 1990, 19, 469-476.	1.5	103
394	Endobronchial irradiation for malignant airway obstruction. International Journal of Radiation Oncology Biology Physics, 1989, 17, 847-851.	1.5	60
395	Radiation induced thyroid neoplasms 1920 to 1987: A vanishing problem?. International Journal of Radiation Oncology Biology Physics, 1989, 16, 1471-1475.	1.5	33
396	Cerebrospinal fluid pressure in normal obese subjects and patients with pseudotumor cerebri. Neurology, 1983, 33, 1386-1386.	1.0	226

#	ARTICLE	IF	CITATIONS
397	Barriers to accrual and enrollment in brain tumor trials. <i>Neuro-Oncology</i> , 0, , .	1.0	46
398	Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design. <i>Neuro-Oncology</i> , 0, 27, 1670-1685.	1.0	15
399	Response Assessment in Neuro-Oncology (RANO) 2009â€“2025: Broad scope and implementationâ€”A progress report. <i>Neuro-Oncology</i> , 0, 27, 2209-2224.	1.0	6
400	Unraveling the effects of radiotherapy on the blood-brain barrier: Fact or fiction?. <i>Neuro-Oncology</i> , 0, 27, 2262-2264.	1.0	0
401	Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 0, , .	1.0	4
402	Intracranial metastases from solid tumors: Call to action and consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology collaborative. <i>Neuro-Oncology</i> , 0, , .	1.0	1
403	Radiation therapy alone versus radiation therapy plus radiofrequency ablation/vertebral augmentation for painful spine metastasis: A phase 2 randomized controlled trial. <i>Neuro-Oncology</i> , 0, , .	1.0	0
404	Redefining neurocognitive outcomes after radiation for brain metastases: a patient-level meta-analysis of recovery following initial decline. <i>Journal of the National Cancer Institute</i> , 0, , .	4.6	2
405	Tumor Treating Fields Therapy After Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer: Final Results of the Phase 3 METIS Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 0, 124, 278-293.	1.5	2
406	Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma. <i>Neuro-Oncology</i> , 0, , .	1.0	1
407	Quantifying risk of radiation necrosis: Normal tissue complication probability modeling following stereotactic radiosurgery for small brain metastases in the modern era. <i>Radiotherapy and Oncology</i> , 0, 214, 111266.	2.0	1